| 6 Ways to Trade FDA and Clinical Trial News Mike Havrilla submits:Beyond the strategy of selecting a basket of small/micro-cap stocks with pending binary events such as FDA decisions and clinical trial results, another means of achieving diversification is by selecting a basket of companies with different types of pending catalysts. Below are some examples of how to categorize pending bio-catalyst events and some specific examples for each category.Bio Run-Up StrategyThis is a common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than $1 billion market cap stocks) with pending binary events (e.g. FDA decision or clinical trial results) approximately 3-6 months ahead of the expected catalyst date and sell into the expected upward momentum in both stock price and trading volume.Complete Story » seekingalpha.com |
Cannabis Drug Launched in U.K. GW Pharmaceuticals' Sativex is the first prescription drug made from cannabis to officially go on sale anywhere in the world. online.wsj.com |
Emergent Seeks Diversity in Trubion Purchase EP Vantage submits:Emergent Biosolutions’ (EBS) purchase of Trubion Pharmaceuticals (TRBN) in a deal worth up to $135.5m is a bid to help the vaccines manufacturer free itself from a dependence on government contracts. In purchasing the autoimmune and oncology specialist, Emergent says it is getting a company with innovative technologies, promising candidates and big pharma partnerships, which will allow it to diversify its research pipeline that currently sits exclusively in the infectious diseases space.The deal was structured as a cash-and-share purchase worth $4.55 for every Trubion share, which closed at $3 Thursday, before the bid was announced. Emergent shares were down 5% in early trading Friday, likely reflecting caution about dilution and the company breaking into a new field. Trubion shares opened nearly 50% higher, nearing Emergent’s purchase price.Complete Story » seekingalpha.com |
U.S. Rebukes Health Insurers The Obama administration told health insurers that it will track those who enact "unjustified" rate increases and may block those companies from a new marketplace for insurance coverage. online.wsj.com |
Matrixx Initiatives CEO Discusses F2Q2011 Results - Earnings Call Transcript Matrixx Initiatives, Inc. (MTXX)F2Q2011 Earnings Conference CallOctober 26, 2010 11 AM ETComplete Story » seekingalpha.com |